Azelastine + Mometasone nasal spray 140 mcg + 50 mcg
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Azelastine + Mometasone nasal spray 140 mcg + 50 mcg, covering 2023-08-04 to 2023-08-04. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis. [Phase 3]